Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAS181 for Lower Respiratory Tract COVID-19
NCT04354389Phase 3Withdrawn
- Sponsor
- Ansun Biopharma
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of DAS181 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Ansun Biopharma. Primary endpoint: Percent of subjects return to room air at Day 14. Planned start Jul 2020; status: withdrawn.
02
Drugs
DAS181
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04354389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04354389.